T +1 212 819 8580
T +1 212 819 8200
Patent litigation lawyer James Trainor has successfully represented clients in all phases of litigation, through trial and appeal.
Clients also benefit from his significant knowledge of antitrust and commercial litigation, as well as patent counseling. In addition, he provides intellectual property (IP) transactional services, ranging from technology licensing to support for M&A and project finance deals.
Operating across the life sciences, high-tech, telecommunications and transportation industries, James brings insight and experience to matters relating to varied fields including: pharmaceuticals; genetics; drug delivery; microprocessor and circuit design; network systems and database management systems (DBMS); software; solar and wind power; transit engineering; waste management; and cosmetics.
In his commercial litigation practice, James has helped numerous clients to secure provisional remedies. His notable work in this area includes acting as lead IP counsel for the US Department of Energy, in the funding of a major solar energy initiative. He also advises corporates and private equity houses on IP-centric M&A transactions.
Clients also seek James' guidance regarding e-Discovery and Legal Process Outsourcing matters, a complex field in which he is a noted thought leader.
James' active pro bono practice has been marked by distinction from the bench. In McCall v. Astrue (S.D.N.Y), he obtained for his client the reversal of the denial of a 22-year-old Social Security Disability claim. More recently, his pro bono work has focused on his role as outside general counsel to the Rett Syndrome Research Trust, which sponsors research into a cure for the neurological disorder.
James represented Pfizer and UCB in Hatch-Waxman litigation against six defendants for infringement of five patents on the drug TOVIAZ® in the District of Delaware. After a four day trial, won on all issues of validity and infringement on all patents against all defendants. Representing Pfizer and UCB against Mylan in a subsequent litigation in Delaware on the same patents concerning Mylan’s ANDA relating to TOVIAZ®.
James represented Google in litigation concerning teleconferencing and Quality of Service (QoS) assurance products.
James represented Amazon in litigation concerning wireless communication under Institute of Electrical and Electronics Engineers (IEEE) standards.
Representing Wyeth, James defended multiple, patent-based class-action antitrust claims relating to its blockbuster drug Effexor®.
James acted as lead counsel for The Port Authority in litigation concerning notification messaging.
James acted as trial counsel for Pfizer in Hatch-Waxman litigation concerning Pfizer's billion-dollar incontinence drugs Detrol® and Detrol LA®.
James represented Spanish pharmaceutical company Almirall in Hatch-Waxman litigation concerning the Almirall/Johnson & Johnson antimigraine drug Axert®.
James represented Novartis in litigation concerning photodynamic therapy and Novartis's Visudyne® product.
James represented Henlopen in a contract and inventorship dispute concerning cosmetics applicators.
Acting as lead counsel, James represented the plaintiff-heir in a dispute with a New York auction house, concerning the estate of famed Hong Kong film actress Tina Ti.
Acting as lead counsel, James represented global aircraft leasing leader ILFC, in a seizure action against a lessee-debtor.
James represented a Japanese national in a contract and fraud suit concerning private International Space Station tourism.